Article type
Abstract
Background
Globally, there is little collaboration around commissioning, production, or use of evidence. Collaboration is seldom considered, or attempts fail, resulting in heartbreaking duplication of effort and research waste. Given the challenges of producing high-quality evidence syntheses with limited funding, human resources, and time, more effective solutions are required to optimize evidence-based decision-making.
We believe a step-change improvement is possible, and building partnerships is a vital part of the solution. This presentation will outline our innovative Alive partnership on medications for the treatment of type 2 diabetes.
Objectives
The objectives of the Alive partnership are to deliver up-to-date, trustworthy, and affordable evidence on medication for the treatment of type 2 diabetes and to ensure that the evidence is responsive to the context of those who need it.
Methods: We have built an Alive* partnership of evidence users, in this case clinical guideline developers, based on aggregated common evidence needs, which are met through the cocreation and maintenance of a living systematic review. A strong foundational living database of randomized trials and timely updated network meta-analyses with GRADE profiles is used to inform guideline updates by each of our partnership members.
Partnership members have cocreated a protocol that governs the living evidence production to meet everyone’s needs. In addition to the traditional PICO variables, the protocol adds shared scope of evidence by multiple guideline developers, with periodic maintenance and iteration. The members contribute effort and/or funding to sustain the evidence production over time. The initiative is governed by a steering committee, and operations are coordinated by a tactical team that ensures smooth progress across the workflow.
Conclusions
The partnership provides its members with access to up-to-date, trustworthy, fit-for-purpose evidence. The collaborative production of the living evidence base underpinning each member's guideline recommendations is both efficient and sustainable because the cost and workload are shared among the partners. Read more: https://data.aliveevidence.org/communities/t2dmeds.
*Alive is a global alliance of organizations and individuals from across the evidence ecosystem building and testing a collaborative model of evidence commissioning and production (www.aliveevidence.org).
Globally, there is little collaboration around commissioning, production, or use of evidence. Collaboration is seldom considered, or attempts fail, resulting in heartbreaking duplication of effort and research waste. Given the challenges of producing high-quality evidence syntheses with limited funding, human resources, and time, more effective solutions are required to optimize evidence-based decision-making.
We believe a step-change improvement is possible, and building partnerships is a vital part of the solution. This presentation will outline our innovative Alive partnership on medications for the treatment of type 2 diabetes.
Objectives
The objectives of the Alive partnership are to deliver up-to-date, trustworthy, and affordable evidence on medication for the treatment of type 2 diabetes and to ensure that the evidence is responsive to the context of those who need it.
Methods: We have built an Alive* partnership of evidence users, in this case clinical guideline developers, based on aggregated common evidence needs, which are met through the cocreation and maintenance of a living systematic review. A strong foundational living database of randomized trials and timely updated network meta-analyses with GRADE profiles is used to inform guideline updates by each of our partnership members.
Partnership members have cocreated a protocol that governs the living evidence production to meet everyone’s needs. In addition to the traditional PICO variables, the protocol adds shared scope of evidence by multiple guideline developers, with periodic maintenance and iteration. The members contribute effort and/or funding to sustain the evidence production over time. The initiative is governed by a steering committee, and operations are coordinated by a tactical team that ensures smooth progress across the workflow.
Conclusions
The partnership provides its members with access to up-to-date, trustworthy, fit-for-purpose evidence. The collaborative production of the living evidence base underpinning each member's guideline recommendations is both efficient and sustainable because the cost and workload are shared among the partners. Read more: https://data.aliveevidence.org/communities/t2dmeds.
*Alive is a global alliance of organizations and individuals from across the evidence ecosystem building and testing a collaborative model of evidence commissioning and production (www.aliveevidence.org).